AngioDynamics (ANGO) Tops Q1 EPS by 9c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
AngioDynamics Reports Fiscal 2021 First Quarter Financial Results
September 29, 2020 7:00 AM EDTFiscal 2021 First Quarter Highlights
Net sales of $70.2 million increased 6.3% compared to the prior-year quarter, inclusive of the previously disclosed $5.2 million order from the National Health Service (NHS) in the UK Gross margin declined 700 basis points year over year to 50.9% GAAP loss per share of $0.11 and adjusted earnings per share of $0.02 Cash and cash equivalents on August 31, 2020 were $47.9 million, compared to $54.4 million on May 31, 2020 The Company expects fiscal year 2021 net sales between $278 and $284 million and fiscal year 2021 adjusted earnings per share between $0.00 and $0.05... More